Inventor
TAO WENG
US17 patents
⚠️ This page may combine multiple inventors who share the name “TAO WENG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NEUROTECH SA
7 patentsUS6361771B1Mar 26, 2002
ARPE-19 as a platform cell line for encapsulated cell-based delivery
NEUROTECH SA102 citations94
US7115257B1Oct 3, 2006
ARPE-19 as a platform cell line for encapsulated cell-based delivery
NEUROTECH SA50 citations92
US6225448B1May 1, 2001
1gG /transferrin receptor fusion protein
NEUROTECH SA29 citations91
US6197294B1Mar 6, 2001
Cell surface molecule-induced macrophage activation
NEUROTECH SA21 citations91
US6506891B2Jan 14, 2003
Cell surface molecule-induced macrophage activation
NEUROTECH SA2 citations61
US6878544B2Apr 12, 2005
Retinal cell lines with extended life-span and their applications
NEUROTECH SA4 citations60
US7189837B2Mar 13, 2007
Cell surface molecule-induced macrophage activation
NEUROTECH SA0 citations51
NEUROTECH USA INC
7 patentsUS7820195B2Oct 26, 2010
Micronized device for the delivery of biologically active molecules and methods of use thereof
NEUROTECH USA INC16 citations89
US10195140B2Feb 5, 2019
Use of encapsulated cell therapy for treatment of ophthalmic disorders
NEUROTECH USA INC5 citations81
US10456356B2Oct 29, 2019
Use of encapsulated cell therapy for treatment of ophthalmic disorders
NEUROTECH USA INC6 citations80
US11207266B2Dec 28, 2021
Use of encapsulated cell therapy for treatment of ophthalmic disorders
NEUROTECH USA INC2 citations68
US12485087B2Dec 2, 2025
Use of encapsulated cell therapy for treatment of ophthalmic disorders
NEUROTECH USA INC0 citations58
US12357566B2Jul 15, 2025
Use of encapsulated cell therapy for treatment of ophthalmic disorders
NEUROTECH USA INC0 citations58
US10004804B2Jun 26, 2018
Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
NEUROTECH USA INC0 citations46